Влияние блокаторов рецепторов к ангиотензину II и антагонистов кальция на когнитивные функции
https://doi.org/10.21518/2079-701X-2016-4-28-35
Аннотация
В статье приведены определение, классификация и патогенетические механизмы нарушения когнитивных функций при артериальной гипертонии. Обсуждаются возможности антигипертензивных препаратов разных классов в коррекции когнитивных нарушений и профилактике деменции. Рассмотрены потенциальные механизмы коррекции когнитивных функций на фоне лечения блока-торами рецепторов к ангиотензину II и антагонистами кальция.
Ключевые слова
артериальная гипертония,
когнитивные функции,
деменция,
антигипертензивная терапия,
антагонисты рецепторов к ангиотензину II,
лозартан,
антагонисты кальция,
амлодипин,
hypertension,
cognitive functions,
dementia,
antihypertensive therapy,
angiotensin II receptor blockers,
losartan,
calcium antagonists,
amlodipine
Об авторах
О. Д. Остроумова
Московский государственный медико-стоматологический университет им. А.И. Евдокимова; Первый Московский государственный медицинский университет им. И.М. Сеченова
Россия
Россия
Е. И. Первичко
Московский государственный университет им. М.В. Ломоносова
Россия
Россия
Н. Ю. Галеева
Городская клиническая больница №70
Россия
Россия
Список литературы
1. Захаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009, 8 с.
2. Larrieu S, Letenneur L, Orgogozo JM. Incidence and outcome of mild cognitive impairment in a population-based prospective cohort. Neurology, 2002, 59: 1594-1599.
3. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: «МЕДпресс-информ», 248 с.
4. Диагностика и лечение артериальной гипер-тензии. Журнал «Системные гипертензии», 2010, 3: 5-26.
5. Henderson AS. Dementia. World Health Organization, Geneva, 1994, 70 p.
6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A Culebras, J Matias Cuiu, G Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993, pp 1927.
7. Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистойй деменции. В кн. под ред. Н.Н. Яхно, И.В. Дамулина: Достижения в нейроге-риатрии. 1995. Ч. 2. С. 189-231.
8. Awad IA, Masaryk T, Magdinec M. Pathogenesis of subcortical hypertense lesions on MRI of the brain. Stroke, 1993, 24: 1339-1346.
9. Inzitari D, Marinoni M, Ginanneschi A. Patho-physiology of leucoaraiosis. In: New concepts in vascular dementia. A Culebras, J Matias Guiu, G Roman (eds). Barcelona: Prous Science Publishers. 1993: 103-113.
10. Fisher CM. Lacunar strokes and infarcts. Neurology, 1982, 32: 871-876.
11. Hachinski VC, Lassen NA, Marshall J. Multiinfarct dementia. A case of mental deterioration in the elderly. Lancet, 1974, 2: 207-210.
12. Дамулин И.В. Сосудистая деменция. Неврологический Ж., 1999, 3(4): 411.
13. Лурия А.Р Высшие корковые функции человека. Изд. 2. М.: издательство МГУ, 1969.
14. Лурия А.Р. Основы нейропсихологии. М.: издательство МГУ, 1973.
15. Лурия.А.Р. Лобные доли и регуляция психических процессов. М.: изд-во Московского Университета, 1966.
16. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet, 1996, 347: 1141-1145.
17. Launer LI, Masaki K, Petrovitch H, Foley D, Havlik RJ. The assotiation between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA, 1995, 274: 1846-1851.
18. Cacciatore F, Abete P, Ferrara N et al. The role of blood pressure in cognitive impairment in an elderly population. J. of Hypertension, 2002, 15: 0135-0142.
19. Elias PK, D'Agostino RB, Elias MF, Wolf PA. Blood pressure, hypertension, and age as risk factors for poor cognitive performance. Exp. Aging. Res., 1995, 21: 393-417.
20. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle-age in the Whitehall II study. J. Clin. Epidemiol., 2005, 58. 1308-1315.
21. Forette F, Seux M-L, Staessen JA et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med, 2002, 162(18): 2046-2052.
22. Lithell H, Hansson L, Skoog I et al., SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens, 2003, 21: 875-86.
23. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358: 1033-41.
24. Marpillat NL, Macquin-Mavier I, Tropeano A-I, Bachoud-Levi A-C, Maison P. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. Journal of Hypertension, 2013, 31(6): 1073-82.
25. Chiu W-C, Ho W-C, Lin M-H, Lee H-H, Yeh Y-Ch, Wang J-D, Chen P-Ch, Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. Journal of Hypertension, 2014, 32: 938-947.
26. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, Wolozin B. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ, 2010, 340: b5465.
27. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of antihypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. J Alzheimers Dis, 2011, 26: 699-708.
28. Hajjar I, Brown L, Mack WJ, Chui H. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series. Arch. Neurol., 2012, 69(12): 1632-1638.
29. Hanon O, Pequignot R. Relationship between antihypertensive drug therapy and cognitive function in elderly hypertensive patients with memory complaints. J Hypertens., 2006, 24(10): 2101-7.
30. Paran E, Anson O, Lowenthal DT. Cognitive Function and Antihypertensive Treatment in the Elderly: A 6-Year Follow-up Study. American Journal of Therapeutics, 2010, 17: 358-364.
31. Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone A, Carmela Iarussi D, Iacono A. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am. J. Hypertens. 1999, 12: 1130-4.
32. Fogari R, Mugellini A, Zoppi A, Derosa G, Pasotti C, Fogari E, Preti P. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens, 2003, 17: 781-785.
33. Schrader J, Luders S, Diener HC et al. Effects of long-term antihypertensive therapy with losar-tan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study. Med. Klin. (Munich), 2008, 103 (7): 491-499.
34. Boutitie F., Oprisiu R., Achard J.M. et al. Does the change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J. Hypertension, 2007, 25: 1543-1553.
35. Fournier A, Messerli FH, Achard JM and Fernandez L. Cerebroprotection mediated by angiotensin II A hypothesis supported by recent randomized clinical trials. J. Am. Coll. Cardiol., 2004, 43: 1343-1347.
36. Boutitie F, Oprisiu R, Achard JM et al. Does the change in angiotensin II formation caused by antihypertensive drugs affect the risk of stroke? A meta-analysis of trials according to treatment with potentially different effects on angiotensin II. J. Hypertension, 2007, 25: 1543-1553.
37. Blume A, Funk A, Gohlke P, Unger T, Culman J. AT2 receptor inhibition in the rat brain reverses the beneficial of AT1 receptor blockade on neurological outcome after focal brain ischemia. Hypertension, 2000, 36: 256.
38. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke. Eprosartan Compared with Nitrendipine for Secondery Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke, 2005, 36: 1218-1226.
39. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Oian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest, 2007, 117: 3393-3402.
40. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun, 2008, 375: 446-449.
41. Остроумова О.Д., Первичко Е.И. Влияние амлодипина на когнитивные функции у пожилых больных артериальной гипертонией. Фарматека, 2013, 13: 68-74.
42. Parneti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs, 1997, 53: 752-768.
43. Mason RP, Leeds PR, Jacob PF et al. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J. Neurochem., 1999, 72: 1448-56.
44. Zipfel GJ, Lee JM, Choi DW/ Reducing calcium overload in the ischemic brain. N. Engl. J. Med., 1999, 341: 1543-4.
45. Thibault O, Porter NM, Chen KC. Calcium Dysregulation in neuronal aging and Alzheimer's disease: hystory and new directions. Cell. Calcium, 1998, 25: 417-33.
46. Poscale A, Etchoberrigaray R. Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities. Pharmacol Res, 1999, 39: 81-88.
47. Hong YL. The relationship between calcium antagonist-induced hypotension and central monoaminergic system in spontaneously hypertensive rats. Int J Clin Pharmacol Ther Toxicol, 1987, 11: 589-97.
48. Murzenok PP, Huang BS, Leenen FHH. Sympathoinhibition by central and periferal infusion of nifedipine in spontaneously hypertensive rats. Hypertension, 2000, 35: 631-6.
49. Gould RJ, Murphy KMM, Snyder SH. Autoradiographic localization of calcium channel antagonist receptors in rats brain with [3H] nitrendipine. Brain Res, 1985, 330: 217-233.
50. Zakharov V.V., Lokshina A.B. Cognitive impairment in general clinical practice. М., 2009, 8 p.
51. Levin O.S. Diagnosis and treatment of dementia in outpatient practice. М.: MEDpressInform, 248 p.
52. Diagnosis and treatment of hypertension. Sistemnye Gipertenzii, 2010, 3: 5-26.
53. Levin O.S., Damulin I.V. Diffuse white matter changes (leukoaraiosis) and the problem of vascular dementia. Book ed. by N.N. Yakhno, I.V. Damulin: Advances in neurogeriatrics. 1995. P. 2. P. 189-231.
54. Damulin I.V. Vascular dementia. Nevrologicheskiy Zh., 1999, 3(4): 411.
55. Luria A.R. Human higher cortical functions. Ed. 2. М.: MSU, 1969.
56. Luria A.R. Basics of neuropsychology. М.: MSU, 1973.
57. Luriya .R. The frontal lobes and regulation of mental process. М.: MSU, 1966.
58. Ostroumova O.D., Pervichko E.I. Effect of amlodipine on cognitive function in elderly hypertensive patients. Pharmateka, 2013, 13: 68-74.
Рецензия
Для цитирования:
Остроумова О.Д., Первичко Е.И., Галеева Н.Ю. Влияние блокаторов рецепторов к ангиотензину II и антагонистов кальция на когнитивные функции. Медицинский Совет. 2016;(4):28-35. https://doi.org/10.21518/2079-701X-2016-4-28-35
For citation:
Ostroumova O.D., Pervichko E.I., Galeeva N.Y. Effect of angiotensin II receptor blockers and calcium antagonists on cognition. Meditsinskiy sovet = Medical Council. 2016;(4):28-35. (In Russ.) https://doi.org/10.21518/2079-701X-2016-4-28-35
Просмотров: 547
Послать статью по эл. почте 